Neurovascular Research Laboratory, Vall d'Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
Stroke Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Neurosci Lett. 2020 Jan 1;714:134580. doi: 10.1016/j.neulet.2019.134580. Epub 2019 Oct 28.
Patients' outcome prediction after ischemic stroke is still challenging. Aquaporin-4 (AQP4) is a water channel that is up-regulated in the brain after the ischemic event, but its presence in bloodstream of stroke patients has not been previously studied. The aim of this pilot study was to investigate circulating AQP4 levels after stroke and its correlation with infarct growth and neurological outcome. AQP4 level was determined by ELISA in serum from 42 t-PA-treated ischemic stroke patients at admission (before t-PA) and 13 healthy subjects. To assess infarct growth, serial brain diffusion-weighted magnetic resonance images were performed at hospital admission and 1-3 days after. Neurological improvement was defined as a ≥4-point decrease in NIHSS score compared to baseline score. Despite stroke patients and healthy controls had similar baseline circulating AQP4 levels, among strokes AQP4 level negatively correlated with NIHSS score at admission (R= -0.34, p = 0.029) and with infarct growth after 1-3 days of stroke onset (R=-0.36; p = 0.018). Furthermore, baseline AQP4 level was higher in those stroke patients showing a neurological improvement 48 h after stroke onset (p = 0.030) and at hospital discharge (p = 0.037). Baseline AQP4 levels also resulted to be an independent predictor of good neurological outcome at both studied time points (OR: 14.33[1.82-112.92], p = 0.012 at 48 h; OR: 4.86[0.98-24.12], p = 0.053 at discharge) in logistic regression analysis, adjusted by age, sex, baseline NIHSS and significant variables in the univariate analysis. Overall, we have explored circulating AQP4 levels, and our data suggest that AQP4 could be used as a biomarker of neurological recovery in the acute-subacute phase of ischemic stroke.
患者缺血性脑卒中后的预后预测仍然具有挑战性。水通道蛋白 4(AQP4)是一种在缺血事件后大脑中上调的水通道,但之前尚未研究其在脑卒中患者血液中的存在。本研究旨在探讨脑卒中后循环 AQP4 水平及其与梗死灶扩大和神经功能结局的相关性。采用酶联免疫吸附试验(ELISA)检测 42 例接受 t-PA 治疗的缺血性脑卒中患者入院时(t-PA 前)和 13 例健康对照者血清中 AQP4 水平。为了评估梗死灶扩大,在入院时和 1-3 天进行连续的脑弥散加权磁共振成像。神经功能改善定义为与基线 NIHSS 评分相比下降≥4 分。尽管脑卒中患者和健康对照组的基础循环 AQP4 水平相似,但在脑卒中患者中,AQP4 水平与入院时 NIHSS 评分(R= -0.34,p=0.029)和卒中后 1-3 天的梗死灶扩大(R=-0.36;p=0.018)呈负相关。此外,在卒中发病后 48 小时和出院时神经功能改善的脑卒中患者中,基础 AQP4 水平较高(p=0.030 和 p=0.037)。基础 AQP4 水平也是两个研究时间点良好神经结局的独立预测因子(OR:14.33[1.82-112.92],p=0.012 在 48 小时;OR:4.86[0.98-24.12],p=0.053 在出院时),在多变量分析调整年龄、性别、基线 NIHSS 和单变量分析中具有统计学意义的变量后。总的来说,我们探索了循环 AQP4 水平,我们的数据表明 AQP4 可作为缺血性脑卒中急性期和亚急性期神经功能恢复的生物标志物。